In vitro biotransformation and identification of-human cytochrome P450 isozyme-dependent metabolism of tazofelone

Drug Metabolism and Disposition

Volumn 25, Issue 12, 1997, Pages 1383-1388

  Surapaneni, Sekhar S ^a   Clay, Michael P ^b   Spangle, Larry A ^b   Paschal, Jonathan W ^b   Lindstrom, Terry D ^b  

^a ELI LILLY AND COMPANY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; COMPLEMENTARY DNA; CYTOCHROME P450; DRUG METABOLITE; MIDAZOLAM; SULFOXIDE; TAZOFELONE; TROLEANDOMYCIN; UNCLASSIFIED DRUG;

ARTICLE; CHROMATOGRAPHY; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG OXIDATION; DRUG TRANSFORMATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LIVER MICROSOME; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; ISOENZYMES; KINETICS; METABOLIC DETOXICATION, DRUG; MICROSOMES, LIVER; PHENOLS; THIAZOLES; THIAZOLIDINES;

EID: 0031465252     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. S. A. Wrighton, M. Vandenbranden, J. C. Stevens, L. A. Shipley, B. J. Ring, A. E. Retite, and J. R. Cashman: In vitro methods for assessing human hepatic metabolism: Their use in drug development. Drug Metab. Rev. 25, 453-484 (1993).
2. R. L. Slaghter and D. J. Edwards. Recent advances: the cytochrome P450 enzymes. Ann. Pharmacother. 29, 619-624 (1995).
3. S. A. Wrighton and J. C. Stevens: The human hepatic cytochrome P450 involved in metabolism. Crit. Rev. Toxicol. 22, 1-21 (1992).
4. G. T. Tucker: The rational selection of drug interaction studies: implication of recent advances in drug metabolism. Int. J. Clin. Pharmacol. Ther. Toxicol. 30, 550-553 (1992).
5. H. Zou, J. R. Sheller, H. Nu, M. Wood, and A. J. Wood: Ethnic differences in response to morphine. Clin. Pharmacol. Ther. 54, 507-513 (1993).
6. J. P. Jones: Predicting rates of cytochrome P450 mediated bioactivation and its application to the design of safer chemicals. In "Designing Safer Chemicals" (S.C. DeVito, ed.), pp 117-137. ACS Press, Washington, D.C., 1996.
7. T. A. Van Der Hoeven and M. J. Coon: Preparation and properties of partially purified cytochrome P450 and reduced nicotinamide adenine dinucleotide phosphate cytochrome P450 reductase from rabbit liver microsomes. J. Biol. Chem. 249, 6302-6310 (1974).
8. S. A. Wrighton, J. C. Stevens, G. W. Becker, and M. Vandenbranden: Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch. Biochem. Biophys. 306, 240-245 (1993).
9. S. D. Hall, M. A. Hamman, A. E. Retite, L. C. Wienkers, W. F. Trager, M. Vandenbranden, and S. A. Wrighton: Relationship between the levels of cytochrome P250 2C9 and its prototypic catalytic activities in human liver microsomes. Drug Metab. Dispos. 22, 975-978 (1994).
10. C. H. Yun, T. Shimada, and F. P. Guengerich: Purification and characterization of human liver microsomal cytochrome P450 2A6. Mol. Pharmacol. 40, 679-685 (1991).
11. D. Sesardic, A. R. Boobis, B. P. Murray, J. Segura, R. De La Torre, and D. S. Davies: Furafylline is a potent and selective inhibitor of cytochrome P450 1A2. Br. J. Clin. Pharmacol. 29, 651-662 (1991).
12. M. Veronese, P. I. MacKenzie, C. J. Doecke, M. E. McManus, and D. J. Birkett: Tolbutamide and phenytoin hydroxylations by cDNA expressed human liver cytochrome P450 2C9. Biochem. Biophys. Res. Commun. 175, 1112-1118 (1991).
13. K. Chiba, K. Kabayashi, K. Manabe, M. Tani, and T. Ishizaki: Oxidative metabolism of omeprazole in human liver microsomes: Cosegregation with S-mephenytoin 4′-hydroxylation. Pharmacol. Exp. Ther. 266, 52-59 (1993).
14. F. P. Guengrich, D. Kim, and M. Iwasaki: Role of human cytochrome P450 2E1 in the oxidation of many low molecular weight cancer suspects. Chem. Res. Toxicol. 4, 168-179 (1991).
15. D. Pessaye, M. Tinel, D. Larrey, B. Colbert, and G. Babany: Inactivation of cytochrome P450 by a troleandomycin metabolite: Protective role of glutathione. J. Pharmacol. Exp. Ther. 224, 685-691 (1983).
16. J. R. Cashman, S. B. Park, Z. C. Yang, S. A. Wrighton, P. Jacob, and N. L. Benowitz: Metabolism of nicotine by human liver microsomes: Stereoselective formation of trans-nicotine N′-oxide. Chem. Res. Toxicol. 5, 639-646 (1992).
17. B. J. Ring, J. Catlow, T. J. Lindsay, T. Gillespie, L. K. Roskos, B. J. Cerimele, S. P. Swanson, M. A. Hamman, and S. A. Wrighton: Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J. Pharmacol. Exp. Ther. 276, 658-666 (1996).
18. S. A. Wrighton, M. Vandenbranden, J. C. Stevens, L. A. Shipley, B. J. Ring, A. E. Retite, and J. R. Cashman: In vitro methods for assesing human hepatic drug metabolism: their use in drug development. Drug Metab. Rev. 25, 453-483 (1993).
19. D. M. Ziegler: Flavin-containing monooxygenase catalytic mechanism and substrate specificities. Drug Metab. Rev. 19, 1-32 (1988).
20. J. A. Thompson, A. M. Malkinson, M. D. Wand, S. L. Mastovich, E. W. Mead, K. M. Schullek, and W. G. Laudenschlager: Oxidative metabolism of butylated hydroxytoluene by hepatic and pulmonary microsomes from rats and mice. Drug Metab. Dispos. 5, 833-840 (1987).
21. T. Ohe, T. Mashino, and M. Hirobe: Substituent elimination from p-substituted phenols by cytochrome P450, ipso-substitution of the oxygen atom of the active species. Drug Metab. Dispos. 25, 116-122 (1997).
22. J. R. Cashman, S. B. Parks, Z. C. Yang, C. B. Washington, D. Y. Gomez, K. M. Giacomini, and C. M. Brett: Chemical, enzymatic and human enantioselective S-oxygenation of cimetidine. Drug Metab. Dispos. 21, 587-597 (1993).
23. D. M. Ziegler: Flavin-containing monooxygenases: enzymes adapted for multisubstrate specificity. Trends Pharmacol. Sci. 11, 321-324 (1990).